Nevada · 0052A

Intramuscular Administration Of Single Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3ml Dosage, Tris-Sucrose Formulation; Second Dose in Nevada

Nevada Medicare Avg
$40.45
0% below national avg
National Medicare Avg
$40.50
All states combined
Billed Charge (NV)
$75.31
What providers submit
Est. Commercial (NV)
$97.07
National avg: $90.73
Est. Cash / Self-Pay (NV)
$51.05
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

13
Services in NV
12
Providers
N/A
Min Payment
N/A
Max Payment

Nevada Pricing in Context

In Nevada, CPT code 0052A (Intramuscular Administration Of Single Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3ml Dosage, Tris-Sucrose Formulation; Second Dose) carries an average Medicare payment of $40.45 — 0% below the national benchmark of $40.50. 12 providers across the state submitted claims for this procedure in 2023, performing 13 total services. Individual payments in NV ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Nevada is $75.31, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Nevada sits below the national Medicare average, commercial rates in the state may also run lower than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Vaccines & Injections procedures, the estimated commercial insurance price in Nevada lands near $97.07, with self-pay cash prices typically around $51.05. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Intramuscular Administration Of Single Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3ml Dosage, Tris-Sucrose Formulation; Second Dose cost in Nevada?

The average Medicare payment for Intramuscular Administration Of Single Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3ml Dosage, Tris-Sucrose Formulation; Second Dose in Nevada is $40.45, which is 0% below the national average of $40.50. Providers in NV typically bill $75.31 for this procedure.

What does Intramuscular Administration Of Single Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3ml Dosage, Tris-Sucrose Formulation; Second Dose cost with insurance in Nevada?

With commercial insurance in Nevada, Intramuscular Administration Of Single Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3ml Dosage, Tris-Sucrose Formulation; Second Dose costs an estimated $97.07. Without insurance, the estimated cash price is $51.05. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Intramuscular Administration Of Single Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3ml Dosage, Tris-Sucrose Formulation; Second Dose in Nevada?

12 providers in Nevada billed Medicare for Intramuscular Administration Of Single Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3ml Dosage, Tris-Sucrose Formulation; Second Dose in 2023, performing 13 total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Intramuscular Administration Of Single Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3ml Dosage, Tris-Sucrose Formulation; Second Dose cheaper in Nevada than the national average?

Yes — Intramuscular Administration Of Single Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3ml Dosage, Tris-Sucrose Formulation; Second Dose costs 0% below the national average in Nevada. The state average Medicare payment is $40.45 compared to $40.50 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial